Be Prepared for the REACH 2018 Deadline
Our experts developed this white paper to help manufacturers demonstrate compliance with the USP <232> and USP <233> standards that became effective on January 1, 2018 in the United States. This paper will:
- Serve as a guide to the proper risk assessment and testing of drug products in order to demonstrate compliance with USP <232> and USP <233> requirements.
- Provide steps needed for elemental impurities risk assessment and testing to help ensure a fast and efficient path to market for your products.
Complete the form below to download the complimentary white paper: Elemental Impurities: A Guide to Risk Assessment and Testing.